Daily wakame seaweed for people with moderate chronic kidney disease
Tests wakame seaweed for lowering harmful sugar-protein compounds in people with chronic kidney disease.
Key facts
- Who runs it
- Groupe Hospitalier de la Rochelle Ré Aunis
- Where
- La Rochelle, FranceSee the site
- Trial code
- Registry title
- Evaluation of the Effect of a Daily Dose of Wakame Seaweed on Reducing Circulating Concentrations of Advanced Glycation End Products in Patients With Stage III Chronic Kidney Disease
- Status
- Recruiting
- People taking part
- 30 people, planned
- Started
- 27 Jan 2026
- Expected to end
- Oct 2027
- Type of study
- Interventional
- Treatments tested
- Consumption of wakame
- Record updated
- 27 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with stage 3 chronic kidney disease who take standard kidney-protecting medicines. They will eat 5 g of wakame seaweed a day for three months.
- Age
- 18 to 90 years (under 90).
- Sex
- Men and women can join.
- Disease stage
- Chronic kidney disease stage IIIA-B, with kidney function (eGFR by CKD-EPI) of 30 mL/min or more and under 60 mL/min.
- Earlier treatment
- People must already take optimized kidney-protecting treatment (ACE inhibitors, SGLT2 inhibitors). People taking other supplements with seaweed or iodine, such as multivitamins, cannot join.
Main reasons for not taking part
- Under legal protection
- Thyroid disease that is not under control
- Heart failure that has worsened suddenly (decompensated)
- Sudden (acute) kidney injury
- Pregnant or breastfeeding women
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Adult patients not under legal protection
- Patients aged ≥ 18 and < 90 years
- Patients with stage IIIA-B chronic kidney disease (CKD) (estimated GFR by CKD-EPI ≥ 30 mL/min and < 60 mL/min)
- Patients receiving optimized nephroprotective treatment (ACE inhibitors, SGLT2 inhibitors)
- Patients who have signed the informed consent form
- Patients not participating in another clinical study
- Patients affiliated with or benefiting from a social security scheme
Who cannot take part
- Patients with uncontrolled thyroid disorders
- Patients with decompensated heart failure
- Patients under 18 years old or over 90 years old
- Adult patients under legal protection
- Patients consuming other dietary supplements containing seaweed or iodine (e.g., multivitamins)
- Pregnant or breastfeeding women
- Patients with acute kidney injury
- Patients who decline to participate in the study
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Where in France
- Groupe Hospitalier de la Rochelle Re-AunisLa Rochelle, FranceContact: Cécile DuchironTaking people
About the trial
What the trial wants to find out
Persistent glomerular hyperfiltration is a characteristic feature of the early stages of kidney disease and represents a factor in the progression of chronic kidney disease (CKD). In this context, the benefit of low-protein diets (less than 0.8g/kg/day) has been demonstrated in slowing the progression of CKD, although the underlying pathophysiological mechanisms remain unclear.
Read full original descriptionShow less
Some studies suggest that the effects of protein on renal hemodynamics are primarily linked to the quality of the protein, particularly the amount of AGEs (Advanced Glycation End Products) consumed.
Recently, edible seaweeds have gained popularity in Western countries due to their anti-inflammatory, anti-diabetic, and antihypertensive properties. These seaweeds are also associated with the above-average longevity of certain Asian populations who consume them daily. Wakame seaweed (Undaria pinnatifida), which is locally harvested along the French Atlantic coast, has shown promising biological properties, notably antihypertensive and anti-diabetic effects. It has also been recently demonstrated that fucoxanthin, a compound found in high concentrations in wakame, possesses strong anti-AGE activity.
Dietary modifications are essential for nephroprotection, but they are often difficult to implement. This highlights the need to develop approaches that are both acceptable on a daily basis and sustainable in the long term for patients.
A Michelin-starred chef, known for regularly incorporating seaweed into his cuisine, is a sponsor of the project and has validated a set of adapted recipes that will be offered to participants to accompany the daily wakame supplementation.
The investigator's hypothesis is that a daily dose (5 grams of French wakame, dehydrated at low temperature and in flake form), equivalent to the average daily intake in Japan, could reduce circulating AGE levels in patients with stage III CKD. This would provide an additional protective effect when combined with the standard low-protein diet, helping to slow the progression of CKD over the long term.
The group in the trial
- Experimental groupTreatment being tested
Consumption of 5g/day of wakame (Undoria pinnatifida) during one of the three meals of the day for a period of three months.
Treatment: Consumption of wakame
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Evaluation of the Effect of a Daily Dose of Wakame (Undaria Pinnatifida) on Reducing Circulating Concentrations of Advanced Glycation End Products (AGEs: Methylglyoxal) in Patients With Stage III Chronic Kidney Disease
- Plain-language title
- Daily wakame seaweed for people with moderate chronic kidney diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Fit questions
- Built from NCT07729683, who can take part
- Record updated
- 27 July 2026